Peijia Medical (HKG:9996) said Friday that Chinese health regulators have approved the registration of the company's GeminiOne system, a non-invasive transcatheter for heart complications, according to a same-day bourse filing.
The company's GeminiOne is a proposed treatment for mitral regurgitation, a common form of valvular heart disease. Registration is currently underway in the EU, and an early feasibility study is ongoing in the U.S.